Hong Jun Yun, MD
Interventional Cardiology · Palos Park, ILNPI 1396065884
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,650 of the $88,964 with a category attached, or 60.3%. Medtronic accounts for 86.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $30,102 and has fallen 60.1% since, to $11,996 in 2025. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $265.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$77K
- Edwards Lifesciences$3K
- Cathworks, Inc.$3K
- Boston Scientific$3K
- Abbott$1K
- W. L. Gore & Associates, Inc.$226
- plus $2K from 19 others
Across 6 payments — averaging $6445.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$39K
What the payments were for
- Consulting fees$4,5005%
- Speaking & faculty fees$53,65060%
- Travel & lodging$19,97122%
- Food & beverage$10,82812%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 202 | $76,508 |
| Edwards Lifesciences | 25 | $3,456 |
| Cathworks, Inc. | 4 | $3,146 |
| Boston Scientific | 17 | $2,707 |
| Abbott | 14 | $1,086 |
| W. L. Gore & Associates, Inc. | 2 | $226 |
| Cardiva Medical, Inc. | 8 | $225 |
| Novartis | 9 | $178 |
| Shockwave Medical, Inc | 1 | $176 |
| Cardiovascular Systems Inc. | 3 | $175 |
| Pfizer | 9 | $175 |
| Jenavalve Technology, Inc. | 1 | $162 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $157 |
| AstraZeneca | 4 | $96 |
| Scpharmaceuticals Inc. | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Novo Nordisk | 2 | $56 |
| Johnson & Johnson | 3 | $56 |
| Endotronix, Inc. | 1 | $42 |
| Teleflex LLC | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 2 | $41 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $41 |
| Amgen | 2 | $32 |
| Merck | 1 | $16 |
| Terumo Medical Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$64,287
- CoreValve Evolut$6,468
- FFRangio$3,146
- Resolute$2,091
- AVVIGO Guidance System$1,650
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,121
- EVOQUE$1,075
- TRICLIP$703
- SAPIEN 3 Ultra RESILIA$368
- GENERAL - THERAPIES$265
- GENERAL VASCULAR ACCESS$249
- CARDIOFORM Septal Occluder$226
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$176
- JenaValve Pericardial TAVR System$162
- PASCAL$157
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$143
- OPTIS$127
How this compares
$88,964 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 216 | $273,436 |
| EntrestoSacubitril/Valsartan | 57 | $89,554 |
| XareltoRivaroxaban | 48 | $58,735 |
| BrilintaTicagrelor | 13 | $10,002 |
| Metoprolol Succinate | 564 | $9,114 |
| Atorvastatin Calcium | 596 | $6,787 |
| ClopidogrelClopidogrel Bisulfate | 343 | $3,635 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 37 | $2,409 |
| Amlodipine Besylate | 245 | $1,906 |
| Metoprolol Tartrate | 288 | $1,865 |
| Midodrine Hcl | 19 | $1,588 |
| Furosemide | 268 | $1,541 |
| Carvedilol | 155 | $1,516 |
| Losartan Potassium | 132 | $1,371 |
| Lisinopril | 155 | $1,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $175 | $273,436216 claims |
| NovartisEntresto | $178 | $89,55457 claims |
| Johnson & JohnsonXarelto | $56 | $58,73548 claims |
| AstraZenecaBrilinta | $96 | $10,00213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Palos Park
- Ravi RamanaPalos Park$458K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.